Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Testing a PET scan imaging agent for lung cancer in adults
Tests a 68Ga-FAPI PET scan to image non-small cell lung cancer in adults.
Key facts
- Who runs it
- Meander Medisch Centrum
- Where
- Amersfoort, NetherlandsSee the site
- Trial code
- Registry title
- Performance and prognostic value of 68Ga-FAPI PET/CT in non-small cell lung cancer (NSCLC)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 20 people, planned
- Started
- 7 Nov 2023
- Planned end
- 31 Oct 2024
- Type of study
- Interventional
- Record updated
- 24 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-small cell lung cancer. It studies how well a 68Ga-FAPI PET/CT scan works and what it can tell about the course of the disease.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Non-small cell lung cancer. The record does not give a stage.
Where in Netherlands
- Meander Medical CenterAmersfoort, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Testing a PET scan imaging agent for lung cancer in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 24 June 2026